Karthikeyan Narayanan
Director, Stem Cell Core
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Extracellular vesicles (EVs) derived from pluripotent stem cells have been reported to reprogram cancer cells to a more benign phenotype, due to its provision of an embryonic microenvironment. Here, we show that the effect of the EVs on the tumorigenicity of the cancer cell lines is cell type‐dependent. First, we characterized the complement of transcription factors contained in EVs derived from human embryonic and induced pluripotent stem cell lines and subsequently treated MCF7, A431, MDA‐MB‐231, and DLD‐1 cancer cell lines with the EVs derived from these pluripotent stem cell lines. For EV‐treated MDA‐MB‐231 and DLD‐1 cells, we found a decrease in the protein expression of CD44 and C24, which are accepted markers for cancer cell populations enriched with tumor‐initiating cells, a result that corresponds to the previous reports. However, for EV‐treated MCF7 and A431 cells, there was an increase in the protein expression of CD44 and C24 instead, with a corresponding increase in clonogenicity and resistance to a panel of anticancer drugs, when compared to non‐exosome‐treated cells. When subcutaneously implanted in nude mice, EV‐treated MCF7 cells gave rise to tumors of larger size than untreated cells. The cell type‐dependence of the effect of hPSC‐derived EV treatment was postulated to be due to occurrence of an EMT for cells located at different locations along the epithelial–mesenchymal spectrum, leading to either an increase or decrease in tumorigenicity. Therefore, exposure to EVs does not always reduce the tumorigenicity of cancer cells but is cell type‐dependent.
Year:
2026
Recent advancements in nanotechnology have led to the development of multifunctional nanoplatforms that significantly enhance both cancer diagnosis and treatment. Gold-based nanoparticles, such as peptide-functionalized nanostructures and PEG-coated nanorods, offer improved tumor targeting, multimodal imaging (including photoacoustic and fluorescence), and effective photothermal therapy. Similarly, ultrafine iron oxide nanoprobes provide superior tumor imaging, while silver-based nanoparticles exhibit rapid systemic circulation, near-infrared fluorescence, and powerful photothermal properties. Titanium-based nanoplatforms enable a combination of therapies and advanced imaging methods. On the therapeutic side, polymeric nanoparticles (PNPs), silica-based platforms, PEG-based nanoparticles, and graphene oxide-based systems each offer unique advantages for targeted drug delivery and theranostics. PNPs, with tunable size, shape, and surface chemistry, enable controlled drug release and reduced side effects, while silica-based nanoplatforms improve tumor targeting and imaging. PEG-based nanoparticles enhance drug release and tumor penetration, and graphene oxide-based systems facilitate subcellular targeting and synergistic therapies. Collectively, these innovations are paving the way for more efficient, precise, and safer cancer therapies, leading to improved clinical outcomes.
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Reprograming of the dental pulp somatic cells to endothelial cells is an attractive strategy for generation of new blood vessels. For tissue regeneration, vascularization of engineered constructs is crucial to improve repair mechanisms. In this study, we show that dentin matrix protein 1 (DMP1) and HUVEC-ECM scaffold enhances the differentiation potential of dental pulp stem cells (DPSCs) to an endothelial phenotype. Our results show that the differentiated DPSCs expressed endothelial markers CD31 and VE-Cadherin (CD144) at 7 and 14 days. Expression of CD31 and VE-Cadherin (CD144) were also confirmed by immunofluorescence. Furthermore, flow cytometry analysis revealed a steady increase in CD31 and VE-Cadherin (CD144) positive cells with DMP1 treatment when compared with control. In addition, integrins specific for endothelial cells were highly expressed during the differentiation process. The endothelial cell signature of differentiated DPSCs were additionally characterized for key endothelial cell markers using gene expression by RT-PCR, Western blotting, immunostaining, and RNA-seq analysis. Furthermore, the angiogenic phenotype was confirmed by tubule and capillary sprout formation. Overall, stimulation of DPSCs by DMP1 and use of HUVEC-ECM scaffold promoted their differentiation into phenotypically, transcriptionally, and functionally differentiated bonafide endothelial cells. This study is novel, physiologically relevant and different from conventional strategies.
Year:
2024
Collaborators (2)
Joshua Cornman-Homonoff
Assistant Professor
Yale New Haven Hospital
Vazhaikkurichi Rajendran
Professor
West Virginia University
Make your next move.
Prepare your application
Review drafts before you send them.